This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Senior Physician, Department of Internal Medicine, Community Hospital Bonn, Bonn, Germany

Markus Menzen, PhD, is a Senior Physician in endocrinology, diabetology and angiology at the Department of Internal Medicine at the Community Hospital Bonn in Germany. He received his degree in medicine from the Rheinische Friedrich-Wilhelm University in Bonn, Germany, and went on to study neuronal opioid receptors for his doctorate.


Markus is a member of several prestigious boards in Germany, including the German Society of Internal Medicine and the German Society of Endocrinology. He is also a member of the German Diabetes Society where he has a position on the board for a working group in diabetes and cardiology, was conference president of a working group on diabetic foot, and has a role in the German Diabetes Society’s guidelines commission.


Recently, Markus has been involved in recent analyses on the effects of SGLT-2 inhibitors on haematocrit in people with diabetes treated with insulin. His current interests include optimising and implementing personalised treatment for his patients with diabetes, and he has several publications in this field.